I/we don't know who or what is stalling the deal,
Post# of 148186
I recall NP saying long ago that changing the way BP is accustomed to doing business would not be easy. He also said a couple months ago these next few months will be critical to the future of CYDY.....I took this not only as cash struggles until a deal is complete, but also difficulty in getting and going with the best license deal option on the table. These are two obvious reasons everyone is taking their time and not rushing this initial deal. Further behind the scenes why it is more difficult IMO is the complexity of the deal. For example, who gets off-label sales if/when a 2nd license deal is complete for TNBC or any non-HIV indication? The company that licenses the non-HIV indication? Maybe this is an easy answer, but sorting through these legal scenarios likely not so easy. Most other drugs don't have the vast number of large indications that leronlimab does. Secondly, most other license deals are for the regional rights to the drug and not regional rights to a specific indication. IMO this is a good position for us to be in having such large market potential with so many indications and a single and safe drug to treat all of these indications...... however, I can see how this makes the negotiations and legal reviews extremely difficult from both parties.
It is extremely frustrating to continue waiting and watching the share price decline with all the great news that has been announced. I agree with lorbas, Hulk and i_luv_cydy comments about NP setting expectations as he has failed to do so many time in my relatively short period following CYDY. My biggest frustration with this situation is NP setting these expectations, although I can't blame him for not being excited about leronlimab. The expectations is fully on him.